January 2, 2024 10:59 AM EST

AstraZeneca's $40M deal with Allorion; Apollo raises $33M; Xoma's stock buyback

Jaimy Lee

Deputy Editor

Another China-US deal for AstraZeneca: The British drugmaker is paying $40 million upfront to Allorion Therapeutics to develop the company’s L858R …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca's $40M deal with Allorion; Apollo raises $33M; Xoma's stock buyback

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

The brain is Eli Lilly's next target for its obesity meds

The Endpoints 100: The biotech industry braces for Trump 2.0

During Covid, RFK Jr. lobbied against vaccine EUAs for children. As HHS secretary, he could rescind them

Lilly’s oral SERD makes strides in breast cancer with Phase 3 data

Drugs are approved — and made available — faster in US than most of EU, data show

The key to faster, more impactful research? Put patients in the driver’s seat

As­traZeneca's $40M deal with Al­lo­ri­on; Apol­lo rais­es $33M; Xo­ma's stock buy­back

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Drugs are ap­proved — and made avail­able — faster in US than most of EU, da­ta show

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

AstraZeneca's $40M deal with Allorion; Apollo raises $33M; Xoma's stock buyback

The brain is Eli Lilly's next target for its obesity meds

The Endpoints 100: The biotech industry braces for Trump 2.0

During Covid, RFK Jr. lobbied against vaccine EUAs for children. As HHS secretary, he could rescind them

Lilly’s oral SERD makes strides in breast cancer with Phase 3 data

Drugs are approved — and made available — faster in US than most of EU, data show

The key to faster, more impactful research? Put patients in the driver’s seat